The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...

Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 Ensifentrine is a novel selective dual ...

The MarketWatch News Department was not involved in the creation of this content. AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded ...

Miami (August 28, 2025) – Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved ...

Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...

Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease ...

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

Company founded by Frazier Life Sciences, which led the Series A financing with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences ...